药物代谢相关基因介导的中草药药物相互作用研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (3): 346-351.

药物代谢相关基因介导的中草药药物相互作用研究

高利臣, 张伟, 刘昭前, 范岚, 周宏灏

中南大学临床药理研究所,遗传药理学湖南省重点实验室,长沙 410078,湖南

收稿日期:2012-01-06 修回日期:2012-02-08 出版日期:2012-03-26 发布日期:2012-04-20
通讯作者: 范岚,女,副研究员,硕士生导师,研究方向:药物基因组学及遗传药理学。Tel: 0731-4805380, E-mail: fanlan_038038@163.com
作者简介:高利臣,男,博士,讲师,研究方向:临床药理学、药物基因组学。Tel: 0731-84805380, E-mail: gonedog1224@hotmail.com
基金资助:
国家重大新药创制专项(2009ZX09304-003; 2009ZX09501-032);国家863计划(2012AA02A518;2009AA022710;2009AA022703);国家自然科学基金(30801421; 30901834);中南大学基本科研业务重点项目(2010QZZD010);长江学者和创新团队发展计划 (IRT0946);新世纪优秀人才资助计划(NCET-10-0843;NCET-11-0509)

Progress in clinical herb-drug interactions mediated by drug metabolism- related genes

GAO Li-chen, ZHANG Wei, LIU Zhao-qian, FAN Lan, ZHOU Hong-hao

Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, Hunan,China

Received:2012-01-06 Revised:2012-02-08 Online:2012-03-26 Published:2012-04-20

摘要/Abstract

摘要： 中草药既是药物也可作为食品补充剂,其应用在国际上越来越广泛。中草药对细胞色素P450酶及其药物转运体的诱导和抑制是介导中草药-药物相互作用和产生药物临床毒副反应的主要机制。中草药能够通过影响药物代谢酶或转运体基因表达和功能改变其底物药物的血药浓度,可能导致临床上药物毒副反应或治疗失败的发生,产生有重要临床意义的中草药-药物相互作用。研究还发现,中草药对药物代谢酶和转运体的影响也受基因剂量控制,即符合基因剂量效应,因而具有遗传的个体差异。本文概述了近年来药物代谢相关基因介导的中草药-药物相互作用及药物基因组学临床研究的最新进展。

关键词: 中草药, 中西药相互作用, 细胞色素P450酶, 药物转运体, 药物基因组学, 核受体

Abstract: Herbal medicines can be used for both prescriptions or food supplements with a wide range of applications.Inductive or inhibitive effects of herbal medicines on cytochrome P450 enzymes and drug transporters is the main mechanism that mediates herb-drug interactions and produces clinical toxicity. Herbal medicines could alter plasma exposure of substrate drugs for drug metabolizing enzymes or transporters by influencing the expressions and functions of drug metabolizing enzymes or transporters, perhaps resulting in unexpected clinical toxicity or therapeutic failure and leading to herb-drug interactions with clinical importance.Moreover, herb-drug interactions are in accordance with the gene-dosage rule, and therefore have genetic interindividual differences. Research progress of the clinical herb-drug interactions and related pharmacogenomics studies mediated by drug metabolism-related genes are reviewed in this article.

Key words: Herb medicine, HERb-drug interaction, CYP450 enzyme, Drug transporter, Pharmacogenomics, Nuclear receptor

中图分类号:

高利臣, 张伟, 刘昭前, 范岚, 周宏灏. 药物代谢相关基因介导的中草药药物相互作用研究[J]. 中国临床药理学与治疗学, 2012, 17(3): 346-351.

GAO Li-chen, ZHANG Wei, LIU Zhao-qian, FAN Lan, ZHOU Hong-hao. Progress in clinical herb-drug interactions mediated by drug metabolism- related genes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 346-351.

参考文献

[1] Phapale PB, Kim SD, Lee HW, et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus[J]. Clin Pharmacol Ther, 2010, 87(4):426-436.
[2] Herranz JL. Pharmacogenetics, pharmacogenomics and individualised antiepileptic therapy[J]. Rev Neurol, 2006, 10(43):43-49.
[3] Chan AL, Leung HW, Wu JW, et al. Risk of hemorrhage associated with co-prescriptions for Ginkgo biloba and antiplatelet or anticoagulant drugs[J]. J Altern Complement Med, 2011, 17(6):513-517.
[4] Yin OQP, Tomlinson B, Waye MMY, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole[J]. Pharmacogenetics, 2004, 14(12):841-850.
[5] Fan L, Wang G, Wang LS, et al. Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole[J]. Acta Pharmacol Sin, 2007, 28 (10):1685-1692.
[6] Suzanne H, Janny GP, Jochem L, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole[J]. Pharmacogenet Genom, 2004, 75(3):191-197.
[7] Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme[J]. Br J Clin Pharmacol, 2009, 67(2):255-261.
[8] Xu H, Williams KM, Liauw WS, et al. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide[J]. Br J Pharmacol, 2008, 153(7):1579-1586.
[9] Yang LJ, Fan L, Liu ZQ, et al. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes[J]. Eur J Clin Pharmacol, 2009, 65(6):601-608.
[10] Zheng J, Chen B, Jiang B, et al. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo[J]. Arch Pharm Res, 2010, 33(2):243-246.
[11] Tu JH, He YJ, Chen Y, et al. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans[J]. Eur J Clin Pharmacol, 2010, 66(8):805-810.
[12] Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes[J]. Clin Pharmacol Ther, 2005, 77(5):415-426.
[13] Guo Y, Chen Y, Tan ZR, et al. Repeated administration of berberine inhibits cytochromes P450 in humans[J]. Eur J Clin Pharmacol, 2012, 68(2):213-217.
[14] Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo[J]. Clin Pharmacol Ther, 2004, 75(1):89 -100.
[15] 陈欣,李玉珍,方翼, 等. CYP3A4代谢药物的特点及其多态性的研究现状[J]. 中国药房, 2010, 21(22):2097-2099.
[16] Mai I, Stormer E, Bauer S, et al. Impact of St John`s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients[J]. Nephrol Dial Transplant, 2003,8 (4): 819-822.
[17] 韩璐,刘洁. CYP2D6基因多态性及对药物代谢的影响[J]. 中国临床药理学与治疗学, 2011, 16 (1): 105-110.
[18] Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs[J]. J Clin Pharmacol, 2007, 47(5) :566-578.
[19] 刘艳,尹又,陈尧,等.人类孕烷受体遗传变异对遗传药理学和药物代谢的影响[J].中国临床药理学与治疗学, 2007, 12(8):845-849.
[20] Na DH, Ji HY, Park EJ, et al. Evaluation of Metabolism-Mediated Herb-Drug Interactions[J].Chinese Pharmacological Bulletin, 2011, 34(11):1829-1842.
[21] Meyer Zu, Schwabedissen HE, Böttcher K, et al. Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1[J]. Hepatology,2010, 52(5):1797-807.